UK plans special measures for no-deal Brexit scenario

7 December 2018

The UK government has provided an update on its contingency planning surrounding the possibility of a so-called “no deal” Brexit, including measures affecting pharmaceuticals.

On Tuesday, the British Parliament is set to vote on an agreed set of transitional arrangements for trade with the EU after March 29, 2019. If the government cannot secure support for the deal, severe disruption to cross-border trade would remain possible.

British health secretary Matt Hancock said that, should the UK leave without a trade deal in place, the government would use airplanes and fast-track trucks to ensure medicines can bypass any customs delays.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK